The role of CDK4/6 inhibitors in early breast cancer

被引：14

作者：

Gil-Gil, Miguel ^{[1
]}

Alba, Emilio ^{[2
]}

Gavila, Joaquin ^{[3
]}

de la Haba-Rodriguez, Juan ^{[4
]}

Ciruelos, Eva ^{[5
]}

Tolosa, Pablo ^{[5
]}

Candini, Daniele ^{[6
]}

Llombart-Cussac, Antonio ^{[7
,8
]}

机构：

[1] Inst Catala Oncol IDIBELL, Barcelona, Spain

[2] Hosp Clin Univ Virgen Victoria, Dept Med Oncol, Malaga, Spain

[3] Fdn Inst Valenciano Oncol, Valencia, Spain

[4] Hosp Univ Reina Sofia, Inst Invest Biomed Cordoba IMIBIC, Dept Med Oncol, Cordoba, Spain

[5] Univ Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain

[6] Pfizer Oncol, Med Dept, Madrid, Spain

[7] Hosp Arnau Vilanova, Dept Med Oncol, Calle St Clement 12, Valencia 46015, Spain

[8] Univ Catolica Valencia, FISABIO, Valencia, Spain

来源：

BREAST | 2021年 / 58卷

关键词：

Early breast cancer; Cyclin-dependent kinase 4/6 inhibitors; Adjuvant therapy; Palbociclib; Abemaciclib; RIBOCICLIB PLUS LETROZOLE; KINASE; 4/6; INHIBITOR; ENDOCRINE THERAPY; POSTMENOPAUSAL WOMEN; OPEN-LABEL; PALBOCICLIB; RESISTANCE; MULTICENTER; CHEMOTHERAPY; ABEMACICLIB;

D O I：

10.1016/j.breast.2021.05.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2(-)) breast cancer (BC), leading to a strong interest in their possible role in the treatment of early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the results of the large phase 3 adjuvant trials recently released, which have yielded apparently divergent results. We also examine the relevance of biomarkers as response predictive factors for CDI4/6i, the combination between radiotherapy and CDK4/6i, and provide a critical discussion on the evidence that we have so far and future directions of the role of these drugs in the treatment of early BC. (C) 2021 Published by Elsevier Ltd.

引用

页码：160 / 169

页数：10

共 50 条

[31] CDK4/6 inhibitors in advanced breast cancer, what is beyond?
Mohammed, Amrallah A.
Rashied, Hanaa
Elsayed, Fifi Mostafa
ONCOLOGY REVIEWS, 2019, 13 (02) : 125 - 133
[32] CDK4/6 inhibition in early and metastatic breast cancer: A review
de Groot, A. F.
Kuijpers, C. J.
Kroep, J. R.
CANCER TREATMENT REVIEWS, 2017, 60 : 130 - 138
[33] Targeting CDK4/6 in breast cancer
Shanabag, Anusha
Armand, Jessica
Son, Eugene
Yang, Hee Won
EXPERIMENTAL AND MOLECULAR MEDICINE, 2025, 57 (02): : 312 - 322
[34] CDK4/6 inhibitors
不详
CHEMICAL & ENGINEERING NEWS, 2016, : 30 - 31
[35] CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms
Haslam, Alyson
Ranganathan, Sruthi
Prasad, Vinay
Olivier, Timothee
EUROPEAN JOURNAL OF CANCER, 2024, 207
[36] Understanding divergent trial results of adjuvant CDK4/6 inhibitors for early stage breast cancer
Cunningham, Niamh C.
Turner, Nicholas C.
CANCER CELL, 2021, 39 (03) : 307 - 309
[37] SBRT with CDK4/6 inhibitors for oligorecurrent/oligoprogressive breast cancer patients
Ippolito, E.
Onorati, E.
Greco, C.
Fiore, M.
Silipigni, S.
Matteucci, P.
Cerasani, L.
Carrafiello, S.
Palumbo, V.
Ramella, S.
RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1298 - S1298
[38] CDK4/6 inhibitors in HR-positive breast cancer immunotherapy
Shen, Mimi
Ma, Zhiyuan
Zhu, Jiaxing
Wen, Guorong
Jin, Hai
An, Jiaxing
Tuo, Biguang
Liu, Xuemei
Li, Taolang
BIOORGANIC CHEMISTRY, 2025, 154
[39] First clinical experience with CDK4/6 inhibitors in breast cancer therapy
Cobec, Ionut Marcel
Moleriu, Lavinia
Moatar, Aurica Elisabeta
Rempen, Andreas
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (05)
[40] Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
Barroso-Sousa, Romualdo
Shapiro, Geoffrey I.
Tolaney, Sara M.
BREAST CARE, 2016, 11 (03) : 167 - 173

← 1 2 3 4 5 →